Imbruvica
Ibrutinib
- Strength
- 70 mg/mL
- Form
- Suspension
- Class
- Kinase Inhibitor
Pharmacyclics LLC
Imbruvica
Ibrutinib
Listed by Pharmacyclics LLC
- Strength
- 70 mg/1
- Form
- Capsule
- Route
- Oral
- Class
- Kinase Inhibitor
What it contains
- Ibrutinib 70 mg/1
FDA record
| Dosage form | Capsule |
|---|---|
| Route | Oral |
| Drug class | Kinase Inhibitor |
| Approval route | NDA — original brand approval |
| NDC code | 57962-070 |
| FDA application | NDA205552 |
| RxNorm concept | 1442986 |
| Package sizes listed | 1 |
| Marketed since | December 2017 |
Other products containing Ibrutinib
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Imbruvica
Ibrutinib
- Strength
- 140 mg/1
- Form
- Capsule
- Class
- Kinase Inhibitor
Pharmacyclics LLC
Imbruvica
Ibrutinib
- Strength
- 280 mg/1
- Form
- Tablet, Film Coated
- Class
- Kinase Inhibitor
Pharmacyclics LLC
Imbruvica
Ibrutinib
- Strength
- 140 mg/1
- Form
- Tablet, Film Coated
- Class
- Kinase Inhibitor
Pharmacyclics LLC
Imbruvica
Ibrutinib
- Strength
- 420 mg/1
- Form
- Tablet, Film Coated
- Class
- Kinase Inhibitor
Pharmacyclics LLC
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.